摘要
目的探讨肾透明细胞癌(CCRCC)患者肿瘤组织中CD146 mRNA的表达及意义。方法用ELISA法定量检测CD146蛋白含量及Real-Time PCR技术检测102例CCRCC患者肿瘤组织中CD146 mRNA的表达,并以51例肾脏良性病变患者手术正常肾组织作为对照。结果发现存在转移的CCRCC患者,CD146蛋白浓度与对照组比较差异有统计学意义(F=52.1,P<0.01),CD146 mRNA的平均表达值(0.043 8±0.002 4)明显高于原位CCRCC患者(0.038 2±0.001 1,P=0.018)和对照组患者(0.034 4±0.001 0,P=0.001)。结论 CD146 mRNA表达上调与CCRCC的病理分级及淋巴结转移相关,有望成为评判CCRCC恶性程度、转移潜能及预后的一个新指标,为临床的干预性治疗提供可靠依据。
Objective To explore renal clear cell carcinoma （CCRCC） expression and significance of CD146 mR- NA in tumor tissue of patients with. Methods ELISA method for quantitative detection was used for CD146 protein and real-time PCR technique for the detection of CCRCC in 102 （CCRCC） expression in tumor tissue of patients with CD146 mRNA, and 51 cases of renal patients with non tumor tissues as control. Results Found metastasis in patients with CCRCC, the CD146 protein concentration was statistically significant compared with the control group （ F =52. 1, P 〈0. 01 ） ,the average expression of CD146 mRNA value （0. 043 8 ±0. 002 4） was significantly high- er than that of in situ CCRCC patients （0. 038 2±0. 001 1, P = 0. 018） and control group （0. 034 4±0. 001 0, P =0. 001 ）. Conclusion Pathological grading and lymph node up regulation of CD146 mRNA expression in renal cell carcinoma and metastasis, is expected to become a new index, evaluation of malignant degree of CCRCC me- tastasis and prognosis, and provide a reliable basis for the intervention of clinical treatment.
出处
《安徽医科大学学报》
CAS
北大核心
2014年第9期1295-1297,共3页
Acta Universitatis Medicinalis Anhui
基金
国家自然科学基金(编号:81171606)
安徽省科技公共服务平台(编号:PT20081011)
